ESMO 2022 – Springworks aims to Defi expectations

Springworks Therapeutics looks on course to get its lead project, the gamma secretase inhibitor nirogacestat, approved for desmoid tumours, after presenting strong data over the weekend at Esmo.

However, this is a small niche, and the big hope for the group must be multiple myeloma, where nirogacestat is being trialled in combination with several BCMA-targeting agents – an approach underscored by the strengthened partnership between Springworks and GSK last week.